US FDA, Industry Prepare For Potential Spread Of Surging Demand For Children’s Pain Relief OTCs
Executive Summary
FDA “understands that manufacturers expect availability to continue to increase in the near future.” CHPA is working with members “focused on safeguarding the US supply by maximizing capacity to produce and direct product to where it is needed most.”
You may also be interested in...
In Talc Litigation On ‘Baseless Scientific Claims,’ J&J Says Settlement Offers Plaintiffs 'Certainty’
Firm reiterates stance on safety of talc as it reports 7.4% Q1 growth in consumer health product sales contributes to earnings guidance boost. It reports $3.85bn consumer health sales with US sales up 11.4% to $1.74bn and international sales 4.4% to $2.12bn.
J&J Limited On Offering Consumer Business Separation Details, Clear On Q4 Revenue Drag
“We made significant progress towards the separation of Kenvue,” says CEO Jaoquin Duoto. But fourth-quarter and full-year progress on consumer sales growth was impeded by loss to foreign currency exchange.
US Consumer Health Industry In 2023: With Supply Chain Concerns Constant, Challenges Loom Larger
OTC drug and dietary supplement industry trade group executives discuss questions on potential market and regulatory developments affecting their members’ businesses. HBW Insight begins reporting from those talks with outlook for supply chain nd production disruptions and prevalence of COVID-19 and other widespread viruses.